사나 바이오테크놀로지(SANA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.08 (-0.65%), 시가총액 $0.85B, 52주 최저~최고 $1.99 ~ $5.92.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologi
사나 바이오테크놀로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사나 바이오테크놀로지의 현재 주가는 $3.08 (-0.65%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사나 바이오테크놀로지의 시가총액은 약 $0.85B입니다.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various thera